An open-label phase I dose-finding study of APR-246 in hematological malignancies

Blood Cancer J. 2016 Jul 15;6(7):e447. doi: 10.1038/bcj.2016.60.

Authors

S Deneberg¹, H Cherif², V Lazarevic³, P-O Andersson⁴, M von Euler⁵, G Juliusson³, S Lehmann^{1

2}

Affiliations

¹ Karolinska University Hospital, Center of Hematology and Karolinska Institutet, Institution of Medicine, Huddinge, Sweden.
² Department of Medical Sciences, Uppsala University and Uppsala Academic Hospital, Uppsala, Sweden.
³ Department of Hematology, Skane University Hospital, Lund, Sweden.
⁴ Section of Hematology, South Älvsborg Hospital, Borås and Sahlgrenska Academy, Gothenburg, Sweden.
⁵ Aprea AB, Solna, Sweden.

No abstract available

Publication types

Clinical Trial, Phase I
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Antineoplastic Agents / administration & dosage*
Antineoplastic Agents / adverse effects
Dose-Response Relationship, Drug
Female
Hematologic Neoplasms / drug therapy*
Hematologic Neoplasms / pathology
Humans
Male
Maximum Tolerated Dose
Middle Aged
Quinuclidines / administration & dosage*
Quinuclidines / adverse effects
Treatment Outcome

Substances

Antineoplastic Agents
Quinuclidines
eprenetapopt